NO20062104L - Kombinasjonsterapi for HCV-infeksjon - Google Patents

Kombinasjonsterapi for HCV-infeksjon

Info

Publication number
NO20062104L
NO20062104L NO20062104A NO20062104A NO20062104L NO 20062104 L NO20062104 L NO 20062104L NO 20062104 A NO20062104 A NO 20062104A NO 20062104 A NO20062104 A NO 20062104A NO 20062104 L NO20062104 L NO 20062104L
Authority
NO
Norway
Prior art keywords
present
hcv infection
combination therapy
relates
combinations
Prior art date
Application number
NO20062104A
Other languages
English (en)
Norwegian (no)
Inventor
Ene Ette
John J Alam
Robert Stephen Kauffman
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20062104L publication Critical patent/NO20062104L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20062104A 2003-10-11 2006-05-10 Kombinasjonsterapi for HCV-infeksjon NO20062104L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51073303P 2003-10-11 2003-10-11
PCT/US2004/033739 WO2005037274A1 (en) 2003-10-11 2004-10-12 Combination therapy for hcv infection

Publications (1)

Publication Number Publication Date
NO20062104L true NO20062104L (no) 2006-05-10

Family

ID=34465143

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062104A NO20062104L (no) 2003-10-11 2006-05-10 Kombinasjonsterapi for HCV-infeksjon

Country Status (17)

Country Link
US (1) US20050112093A1 (cg-RX-API-DMAC7.html)
EP (1) EP1670462A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007508326A (cg-RX-API-DMAC7.html)
KR (1) KR20060120037A (cg-RX-API-DMAC7.html)
CN (1) CN1882335A (cg-RX-API-DMAC7.html)
AR (1) AR045870A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004281747A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415249A (cg-RX-API-DMAC7.html)
CA (1) CA2541857A1 (cg-RX-API-DMAC7.html)
IL (1) IL174864A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004077A (cg-RX-API-DMAC7.html)
NO (1) NO20062104L (cg-RX-API-DMAC7.html)
PE (1) PE20050477A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006115916A (cg-RX-API-DMAC7.html)
TW (1) TW200528104A (cg-RX-API-DMAC7.html)
WO (1) WO2005037274A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602912B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US20120201883A1 (en) * 2004-05-21 2012-08-09 Accu-Break Technologies, Inc Antiviral compositons
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
CA2617679A1 (en) * 2005-08-02 2007-02-08 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
JP2009531315A (ja) 2006-03-16 2009-09-03 バーテックス ファーマシューティカルズ インコーポレイテッド 重水素化c型肝炎プロテアーゼインヒビター
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
FR2928146B1 (fr) * 2008-02-28 2010-02-19 Saint Gobain Isover Produit a base de fibres minerales et son procede d'obtention.
JP5539363B2 (ja) * 2008-09-17 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ
JP2012517478A (ja) * 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、hcv組合せ治療剤
EP2450051A4 (en) * 2009-06-30 2012-12-19 Meiji Seika Pharma Co Ltd MEDICAL AGENT AND METHOD FOR THE TREATMENT OF HARD-ANGLE CHRONIC HEPATITIS C
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
PH12012500827A1 (en) 2009-10-30 2013-01-07 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017223178A1 (en) * 2016-06-21 2017-12-28 Trek Therapeutics, Pbc Treating viral infections with impdh inhibitors
KR101991365B1 (ko) * 2017-03-14 2019-06-21 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도
CN109745315B (zh) * 2019-03-08 2021-04-16 中国农业科学院兰州兽医研究所 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126674A (en) * 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
IL139220A0 (en) * 1998-05-15 2001-11-25 Schering Corp Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
US6824769B2 (en) * 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
US20040034206A1 (en) * 2002-05-31 2004-02-19 Schering Corporation Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors

Also Published As

Publication number Publication date
CA2541857A1 (en) 2005-04-28
CN1882335A (zh) 2006-12-20
EP1670462A1 (en) 2006-06-21
PE20050477A1 (es) 2005-08-24
AU2004281747A1 (en) 2005-04-28
RU2006115916A (ru) 2007-12-10
IL174864A0 (en) 2008-04-13
ZA200602912B (en) 2007-06-27
TW200528104A (en) 2005-09-01
US20050112093A1 (en) 2005-05-26
WO2005037274A1 (en) 2005-04-28
BRPI0415249A (pt) 2006-12-12
JP2007508326A (ja) 2007-04-05
AR045870A1 (es) 2005-11-16
MXPA06004077A (es) 2006-06-27
KR20060120037A (ko) 2006-11-24

Similar Documents

Publication Publication Date Title
NO20062104L (no) Kombinasjonsterapi for HCV-infeksjon
UA103496C2 (uk) Комбінація інгібітора протеази ns3 hcv з інтерфероном і рибавірином
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
WO2004099246A3 (en) Peptides for use in treating obesity
WO2006130627A3 (en) Methods for treating hepatitis c
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
PL374865A1 (en) Treatment of tnf alpha related disorders
CY1112790T1 (el) Χρηση μαγιας σεληνιου στην αντιμετωπιση της νοσου αλτσχαιμερ
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
DE60207890D1 (de) Neue verbindungen
PH12012500827A1 (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
DK1476468T3 (da) Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
MX2009011930A (es) Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
NO20054744L (no) Behandling av Alzheimers sykdom
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
BRPI0511367B8 (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
ATE451934T1 (de) Pharmazeutische zusammensetzung zur behandlung von rhinitiden
SE0302304D0 (sv) Novel compounds
NO20065859L (no) Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser
DE602006012115D1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application